Free tool
FAERS Monitor: Baraclude
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021798 or its brand name (Baraclude, Entecavir). Reports on generic versions are filed under their own applications.
Reports
11,801
Serious
10,278
87% of reports
Hospitalization
4,532
Death reported
1,893
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death554
- off label use553
- drug ineffective451
- drug resistance407
- diarrhoea389
- pyrexia372
- fatigue369
- hepatitis b332
- nausea328
- pneumonia309
- platelet count decreased302
- anaemia238
- renal impairment236
- hepatic failure233
- neutropenia229
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 15 |
| 2006 | 64 |
| 2007 | 193 |
| 2008 | 160 |
| 2009 | 234 |
| 2010 | 308 |
| 2011 | 317 |
| 2012 | 433 |
| 2013 | 378 |
| 2014 | 654 |
| 2015 | 652 |
| 2016 | 823 |
| 2017 | 761 |
| 2018 | 787 |
| 2019 | 858 |
| 2020 | 740 |
| 2021 | 758 |
| 2022 | 793 |
| 2023 | 783 |
| 2024 | 796 |
| 2025 | 755 |
| 2026 | 537 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,358 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatitis bSignal | 332 | 103.9 | 93.1 | 31,870 |
| drug resistanceSignal | 407 | 28.7 | 26.0 | 10,686 |
| hepatic failureSignal | 233 | 13.9 | 12.2 | 2,753 |
| platelet count decreasedSignal | 302 | 5.1 | 4.5 | 982 |
| renal impairmentSignal | 236 | 5.0 | 4.4 | 756 |
| neutropeniaSignal | 229 | 3.0 | 2.6 | 306 |
| anaemiaSignal | 238 | 2.2 | 2.0 | 161 |
| pyrexia | 372 | 1.9 | 1.7 | 165 |
| pneumonia | 309 | 1.7 | 1.5 | 90 |
| death | 554 | 1.1 | 1.1 | 11 |
| off label use | 553 | 1.1 | 1.0 | 8 |
| diarrhoea | 389 | 1.1 | 1.0 | 2 |
| fatigue | 369 | 0.8 | 0.8 | 11 |
| nausea | 328 | 0.7 | 0.7 | 31 |
| drug ineffective | 451 | 0.6 | 0.6 | 120 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.